EUCTR2015-003625-34-NL进行中（未招募）1 期
A randomised, double-blind, placebo-controlled, proof-of-concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis
Boehringer Ingelheim bv0 个研究点目标入组 251 人开始时间: 2016年2月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 251
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Have PsA symptoms for >/= 6 months prior to screening, as assessed by the investigator
- •- Have PsA on the basis of the Classification Criteria for Psoriatic Arthritis (CASPAR) with peripheral symptoms at screening visit, as assessed by the investigator
- •- Have >/= 5 tender joints and >/= 5 swollen joints at screening and randomisation visits, as assessed by the investigator
- •- At least one PsO lesion or a documented personal history of PsO at screening, as assessed by the investigator
- •- If patients receive concurrent PsA treatments, these need to be on stable doses
- •- Active PsA that has been inadequately controlled by standard doses of NSAIDs administered for >/= 4 weeks, or traditional DMARDs (including sulfasalazine) administered for >/= 3 months, or TNFi agents, or subjects are intolerant to NSAIDs or DMARDs or TNFi agents, as assessed by the investigator
- •- Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation
- •- Further inclusion criteria apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 170
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Major chronic inflammatory or connective tissue disease other than PsA (e.g. rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, Lyme disease, gout) and fibromyalgia, as assessed by the investigator
- •- Has received any therapeutic agent directly targeted to IL-12/23 (including ustekinumab), IL-23 or IL-17 (including secukinumab)
- •- Prior use of more than two different TNFi agents
- •- Use of the following treatments: TNFi agents within 12 weeks, etanercept within 8 weeks, leflunomide without cholestyramine wash-out within 8 weeks, systemic non-biologic medications for psoriatic arthritis or psoriasis and photochemotherapy within 4 weeks, intraarticular injections (including steroids) and intramuscular or intravenous corticosteroid treatment within 4 weeks, topical psoriasis medications and phototherapy within 2 weeks, low and high potency opioid analgesics within 2 weeks prior to randomisation
- •- Plans for administration of live vaccines during the study period or within 6 weeks prior to randomisation
- •- History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients
- •- Active systemic infections during the last 2 weeks (exception: common cold) prior to randomisation, as assessed by the investigator
- •- Chronic or relevant acute infections including HIV, viral hepatitis and (or) active tuberculosis. Patients with a positive QuantiFERON TB or PPD test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then tuberculosis treatment may be deferred until completion of the trial according to clinical judgment of investigator and local country guidelines.
- •- Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix
- •- Major surgery performed within 12 weeks prior to randomisation or planned within 32 weeks after randomisation (e.g. hip replacement, aneurysm removal, stomach ligation), as assessed by the investigator
- •- Total white blood count (WBC) < 3,000/µL, or platelets < 100,000/µL or neutrophils < 1,500/µL, or hemoglobin <8.5 g/dL at screening
- •- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2x the upper limit of normal, or serum direct bilirubin = 1.5 mg/dL at screening
- •- Positive rheumatoid factor or anti-cyclic-citrullinated peptide (anti-CCP) antibodies at screening
- •- Further exclusion criteria apply
研究者
相似试验
进行中（未招募）
1 期
BI 655066/ABBV-066/risankizumab compared to placebo in patients with active psoriatic arthritisActive Psoriatic ArthritisMedDRA version: 19.1Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2015-003625-34-CZBoehringer Ingelheim RCV GmbH & Co KG251
进行中（未招募）
1 期
BI 655066 / ABBV-066 / risankizumab compared to placebo in patients with active psoriatic arthritisActive Psoriatic ArthritisMedDRA version: 19.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2015-003625-34-FIBoehringer Ingelheim Finland Ky251
进行中（未招募）
1 期
A study to evaluate the effect of quinagolide extended-release vaginal ring on reduction of lesions, assessed by high-resolution MRI, in women with endometrioma, deep inflitrating endometriosis and/or adenomyosis.EUCTR2018-000915-26-ITFerring Pharmaceutical A/S67
进行中（未招募）
1 期
BI 655066/ABBV-066/risankizumab compared to placebo in patients with active psoriatic arthritisEUCTR2015-003625-34-DEBoehringer Ingelheim Pharma GmbH & Co. KG180
进行中（未招募）
1 期
BI 655066 compared to placebo in patients with active psoriatic arthritisActive Psoriatic ArthritisMedDRA version: 18.1Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2015-003625-34-ESBoehringer Ingelheim España, S.A.251